We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cisbio Bioassays Marks Second Milestone in China with new Demo Lab

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cisbio Bioassays Marks Second Milestone in China with new Demo Lab"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Cisbio Bioassays, a member of IBA group and global developer of HTRF® (Homogeneous Time-Resolved Fluorescence) technology and services used in assay development and drug screening, announced that it has established a new technical support and service laboratory (the HTRF demo lab) in Shanghai, China, thereby reinforcing its business operations in one of the world’s fastest emerging pharmaceutical and biotechnology markets.

The HTRF demo lab enables Cisbio Bioassays to provide enhanced drug discovery services to its pharmaceutical, CRO and academic laboratory customers in China and surrounding areas. Services include seminars on the principle of HTRF technology, custom labeling and assay development, troubleshooting and problem solving, particularly in the areas of G-Protein Coupled Receptor (GPCR) and kinase investigation.

Situated at the Zhangjiang High-Tech Park, the hub of the multi-national pharmaceutical industry in China, the HTRF demo lab was set up in collaboration with China’s National Center for Drug Screening (NCDS), one of China’s leading drug screening centers. The NCDS is affiliated with the Shanghai Institute of Materia Medica (SIMM), a leading drug development research institute, and the Chinese Academy of Sciences.

“Developing assays locally, with locally-produced antibodies, minimizes the logistical hurdles researchers would otherwise face during assay development when they must outsource to third parties in the U.S. or Europe,” said Dr. Bing Xie, director, Asia PacRim, Cisbio Bioassays. “Our new HTRF demo lab will eliminate this problematic for our Chinese customers and enable them, in particular ones who do not have appropriate readers, to better understand HTRF technology and develop their own assays through an accelerated access to our platform.”

“Our second step in China marks an important milestone in confirming our mission to be a best-in-class service- and customer-oriented company in every major market,” said François Degorce, director of marketing for Cisbio Bioassays. “Our Shanghai-based HTRF demo lab now enables us to better deploy our HTRF technology platform with top-notch partners in the area, and provide the same caliber services to our new customers in Asia as we already do in the U.S., in Europe and in Japan.”